Latest News Archive
Please select Category, Year, and then Month to display items
11 January 2021
|
Story André Damons
|
Photo Supplied
Dr Ralph Clark
The Afromontane Research Unit (ARU), the flagship research group of the University of the Free State (UFS) Qwaqwa Campus, has recently been granted R8,4 million to establish a Risk and Vulnerability Science Centre programme.
The Risk and Vulnerability Science Centre (RVSC) programme was established by the Department of Science and Innovation (DSI) as part of the Global Change Research Plan for South Africa and is funded by the DSI through the National Research Foundation (NRF). The RVSC will focus on the need to generate and disseminate knowledge about risk and vulnerability on global change challenges faced by local policy makers/ governance structures and communities in South Africa.
Invited to participate
Dr Ralph Clark, Director of the ARU, says the UFS, together with the University of Zululand and the Sol Plaatje University, has been invited to participate in Phase 2 of the RVSC programme. Dr Clark was approached by the DSI (on referral from the South African Environmental Observation Network – SAEON) in February 2020 regarding the potential for establishing a RVSC at the UFS Qwaqwa campus.
Subsequent interactions were held between the UFS and DSI, and in March 2020, the UFS formally accepted the DSI invitation. It has since been agreed that the RVSC: UFS will be hosted as a RVSC under the ARU umbrella, with dedicated personnel embedded at the UFS in this regard (internal processes and reporting) but reporting directly to the NRF regarding the RVSC.
Interest and support welcomed
Dr Clark welcomed this interest and support from the DSI-NRF, saying that the funds will further assist the UFS in growing its excellent and growing research portfolio and building more research capacity on this traditionally undergraduate-focused campus. “The RVSC will contribute to much-needed solutions in an area marked by major sustainability challenges and will assist in moving Phuthaditjhaba away from its negative apartheid history towards becoming a sustainable African mountain city,” says Dr Clark.
DNA sequencer launched at the UFS
2013-11-25
 |
| Dr Gansen Pillay, Deputy Chief Executive Officer of the National Research Foundation, explaining to the scholars what will be expected of them. |
The University of the Free State (UFS) can now collect immensely valuable data on drug resistance in HIV/Aids and TB with the new DNA sequencer that was launched recently at the International workshop on HIV/AIDS and TB drug resistance at the Bloemfontein Campus.
The DNA sequencer will allow the Free State province to produce viral and bacterial genetic data to fight the local development of HIV/ Aids and TB drug resistance.
The HIV and TB epidemics have expanded very fast and South Africa now has the largest HIV and TB treatment programme in the world, with over 2 million patients on treatment. However, these successful treatment programmes are now being threatened by the appearance of drug resistance.
The Free State province has been at the forefront of fighting HIV drug resistance in South Africa and has one of the most advanced treatment programmes for the management of resistance strains in the country. In addition, researchers at the University of the Free State are leading partners in the Southern African Treatment and Resistance Network (SATuRN; www.bioafrica.net/saturn), a research network that has trained over 2 000 medical officers in the treatment of drug resistance strains.
The Department of Medical Microbiology and Virology in the Medical School at the UFS has partnered with the provincial department of health, the Medical Research Council (MRC) and the Delegation of the European Union to South Africa to fund a dedicated DNA sequencer machine that will be used to generate HIV and TB drug-resistance results. This new machine will enable cutting-edge research to take place, using the data in the province and, importantly, support patients with resistance strains to have access to advanced genotypic testing techniques.
“HIV drug resistance is a very serious problem in South Africa, and the recent advances in DNA testing technology allow clinicians in the province to access drug resistance testing, which enables them to manage patients appropriately who fail treatment, and use the results to cost-effectively extend and improve patients’ lives,” says Dr Cloete van Vuuren, Specialist in Infectious Diseases at the UFS’s Faculty of Health.
Dr Dominique Goedhals, pathologist from the Department of Medical Microbiology and Virology at the UFS, adds: “We have been looking forward to expanding our work with the clinicians and researchers, using DNA sequencing to shed light on the causes and consequences of drug resistance in urban and rural settings in the province.”